

KRAZATI[®]
(adagrasib) | 200 mg
TABLETS

IN *KRAS G12C*-POSITIVE ADVANCED NSCLC
This is my non-small
REVOLUTION

This is your guide to understanding treatment after prior therapy, expectations when starting KRAZATI, and support that may help you along the way.

Not an actual patient.



+ For additional information and resources, visit www.KRAZATI.com.

What is KRAZATI?

KRAZATI is a prescription medicine used in adults:

- alone to treat non-small cell lung cancer (NSCLC)
 - that has spread to other parts of the body or cannot be removed by surgery, **and**
 - whose tumor has an abnormal KRAS G12C gene, **and**
 - who have received at least one prior treatment.

Your healthcare provider will perform a test to make sure that KRAZATI is right for you.

It is not known if KRAZATI is safe and effective in children.

SELECT IMPORTANT SAFETY INFORMATION

Before taking KRAZATI, tell your healthcare provider about all of your medical conditions, including if you:

- have any heart problems, including heart failure and congenital long QT syndrome
- have liver problems
- are pregnant or plan to become pregnant. It is not known if KRAZATI can harm your unborn baby
- are breastfeeding or plan to breastfeed. It is not known if KRAZATI passes into your breastmilk. Do not breastfeed during treatment and for 1 week after your last dose of KRAZATI

Please read the Full Important Safety Information on pages 9-10 and please see the [Full Prescribing Information](#), including [Patient Information](#).

what IS KRAZATI?

KRAZATI[®]
(adagrasib) | 200 mg
TABLETS

KRAZATI is a prescription medicine used to treat adults with non-small cell lung cancer (NSCLC) that has spread to other parts of the body or cannot be removed by surgery, and whose tumor has an abnormal *KRAS G12C* gene, and who have received at least one prior treatment for their cancer.

Your healthcare provider will perform a test to make sure KRAZATI is right for you.

It is not known if KRAZATI is safe and effective in children.

Designed With Your Specific Type of Cancer in Mind

KRAZATI is not chemotherapy; it is a targeted therapy focused on targeting your disease.



Not an actual patient.

SELECT IMPORTANT SAFETY INFORMATION

Tell your healthcare provider about all the medicines you take, including prescription and over-the-counter medicines, vitamins, and herbal supplements. KRAZATI can affect the way other medicines work, and other medicines can affect how KRAZATI works.


Please read the Full Important Safety Information on pages 9-10 and please see the [Full Prescribing Information](#), including [Patient Information](#).

how

KRAZATI[®]
(adagrasib) | 200 mg
TABLETS

KRAZATI TARGETS KRAS G12C

The *KRAS G12C* mutation is one of many mutations that may be found in NSCLC. The growth and development of cells can be controlled by *KRAS*.



KRAS makes a protein that, when mutated, like *KRAS G12C*, can set off a domino effect that can lead to cancer.



KRAZATI is designed to target *KRAS G12C* to help fight specific proteins that help cause tumors to grow and spread throughout the body.

▶▶▶▶ **KRAZATI is designed to suppress
KRAS G12C tumor growth.**

SELECT IMPORTANT SAFETY INFORMATION

KRAZATI can cause serious side effects, including:

- **Stomach and intestinal (gastrointestinal) problems.**
Stomach and intestinal side effects, including nausea, diarrhea, or vomiting, are common with KRAZATI but can also sometimes be severe. KRAZATI can also cause serious stomach and intestinal side effects such as bleeding, obstruction, inflammation of the colon (colitis), and narrowing (stenosis)
 - **Call your healthcare provider if you develop any of the signs or symptoms of stomach or intestinal problems listed above during treatment with KRAZATI**
 - Your healthcare provider may prescribe an antidiarrheal medicine or anti-nausea medicine, or other treatment, as needed

Please read the Full Important Safety Information on pages 9-10 and please see the [Full Prescribing Information](#), including [Patient Information](#).



Not an actual patient.

what

KRAZATI[®]
(adagrasib) | 200 mg
TABLETS

WERE THE STUDY RESULTS?

KRAZATI was tested in a clinical trial of 116 adults with NSCLC. The trial evaluated how many patients responded to KRAZATI, meaning their tumors shrank or disappeared, as well as how long the tumor responded to KRAZATI.



43% saw tumors shrink or disappear

(Objective response rate)

Based on 112 people, of whom 1 person saw all signs of cancer disappear and 47 people saw a decrease in tumor size.



How long did tumors respond to treatment?

(Duration of response)

Of those people (n=112) whose tumor responded to treatment, the duration of response was 8.5 months (median) with KRAZATI.

SELECT IMPORTANT SAFETY INFORMATION

KRAZATI can cause serious side effects, including:

- **Changes in the electrical activity of your heart called QTc prolongation.** Certain changes can occur in the electrical activity of your heart during treatment with KRAZATI, and can be seen on a test called an electrocardiogram (ECG or EKG). QTc prolongation can increase your risk for irregular heartbeats that can be life-threatening, such as torsades de pointes, and can lead to sudden death
 - You should not take KRAZATI if you have congenital long QT syndrome or if you currently have QTc prolongation. See **“Before taking KRAZATI, tell your healthcare provider about all of your medical conditions, including if you:”**
 - Your healthcare provider should monitor the electrical activity of your heart and the levels of body salts in your blood (electrolytes) especially potassium and magnesium before starting and during treatment with KRAZATI if you have heart failure, a slow heart rate, abnormal levels of electrolytes in your blood, or if you take a medicine that can prolong the QT interval of your heartbeat
 - **Tell your healthcare provider if you feel dizzy, lightheaded, or faint, or if you get abnormal heartbeats during treatment with KRAZATI**


Please read the Full Important Safety Information on pages 9-10 and please see the [Full Prescribing Information](#), including [Patient Information](#).

how

SHOULD I TAKE KRAZATI?

Take KRAZATI exactly as your doctor tells you to take it. The recommended dosage is 600 mg twice a day.

KRAZATI Recommended Dosage



- Taken orally (not an injection)
- Take your prescribed dose of KRAZATI 2 times each day, at the same time each day, either with or without food
- Swallow KRAZATI tablets whole. Do not chew, crush, or split tablets
- Your doctor may change your dose, or temporarily or permanently stop treatment with KRAZATI if you develop certain side effects

Do not change your dose or stop taking KRAZATI unless your doctor tells you to.

- If you vomit after taking a dose of KRAZATI, do not take an extra dose. Take your next dose at your next scheduled time

IF YOU MISS A DOSE OF KRAZATI:

- Take it as soon as you remember
- **By more than 4 hours?**
Do not take the dose; take your next dose at your next scheduled time

Do not take 2 doses of KRAZATI at the same time to make up for a missed dose.



FOR ANSWERS TO
FREQUENTLY ASKED
QUESTIONS ABOUT KRAZATI,
SCAN THIS QR CODE.

SELECT IMPORTANT SAFETY INFORMATION

KRAZATI can cause serious side effects, including:

- **Liver problems.** Abnormal liver blood test results are common with KRAZATI and can sometimes be severe. Your healthcare provider should do blood tests before starting and during treatment with KRAZATI to check your liver function. Tell your healthcare provider right away if you develop any signs or symptoms of liver problems, including:
 - your skin or white part of your eyes turns yellow (jaundice), dark or “tea-colored” urine, light-colored stools (bowel movements), tiredness or weakness, nausea or vomiting, bleeding or bruising, loss of appetite, pain, aching, or tenderness on the right side of your stomach area (abdomen)

Please read the Full Important Safety Information on pages 9-10 and please see the [Full Prescribing Information](#), including [Patient Information](#).

ARE THE POSSIBLE SIDE EFFECTS I MAY EXPERIENCE WHILE TAKING KRAZATI?

There is a possibility you will experience side effects while on KRAZATI. KRAZATI may cause serious side effects, including stomach and intestinal (gastrointestinal) problems, changes in the electrical activity of your heart called QTc prolongation, liver problems, and lung or breathing problems.

Stomach and intestinal (gastrointestinal) problems: Stomach and intestinal side effects, including nausea, diarrhea, or vomiting, are common with KRAZATI but can also sometimes be severe. KRAZATI can also cause serious stomach and intestinal side effects such as bleeding, obstruction, inflammation of the colon (colitis), and narrowing (stenosis). **Call your healthcare provider if you develop any of the signs or symptoms of stomach or intestinal problems listed above during treatment with KRAZATI.** Your healthcare provider may prescribe an antidiarrheal medicine or anti-nausea medicine, or other treatment, as needed.

Changes in the electrical activity of your heart called QTc prolongation: Certain changes can occur in the electrical activity of your heart during treatment with KRAZATI, and can be seen on a test called an electrocardiogram (ECG or EKG). QTc prolongation can increase your risk for irregular heartbeats that can be life-threatening, such as torsades de pointes, and can lead to sudden death. You should not take KRAZATI if you have congenital long QT syndrome or if you currently have QTc prolongation. **Tell your healthcare provider if you feel dizzy, lightheaded, or faint, or if you get abnormal heartbeats during treatment with KRAZATI.**

Liver problems: Abnormal liver blood test results are common with KRAZATI and can sometimes be severe. Your healthcare provider should do blood tests before starting and during treatment with KRAZATI to check your liver function. Tell your healthcare provider right away if you develop any signs or symptoms of liver problems. See pages 9-10 for a list of things to watch out for.


Lung or breathing problems: KRAZATI may cause inflammation of the lungs that can lead to death. Tell your healthcare provider or get emergency medical help right away if you have new or worsening shortness of breath, cough, or fever.

The most common side effects of KRAZATI when used alone for NSCLC include: nausea, diarrhea, vomiting, tiredness, muscle and bone pain, kidney problems, swelling, decreased appetite, trouble breathing.

Certain abnormal blood test results are common during treatment with KRAZATI. Your healthcare provider will monitor you for abnormal blood tests and treat you if needed.

KRAZATI may cause fertility problems in males and females, which may affect your ability to have children. Talk to your healthcare provider if this is a concern for you.

The most common side effects of KRAZATI included:



Listen to your body, listen to yourself. If you experience any side effects, it's important to talk to your healthcare provider right away.

Please read the [Full Important Safety Information](#) on pages 9-10 and please see the [Full Prescribing Information](#), including [Patient Information](#).

what

KRAZATI[®]
(adagrasib) | 200 mg
TABLETS

TIPS ARE THERE FOR MANAGING SIDE EFFECTS?

Tips for managing side effects

DIARRHEA

- Drinking fluids may help you stay hydrated
- Eating smaller meals with foods that might be easy on your stomach, such as those high in potassium and sodium, may help replace what your body has lost
- Discuss possible treatments for this symptom with your doctor

NAUSEA AND VOMITING

- Drink plenty of fluids—water and clear liquids
- Eat smaller, more frequent meals. Nausea may be worse on an empty stomach
- Pay attention to which foods bother your stomach and try to avoid them (ie, greasy, fried, sweet, or spicy foods)
- Talk to your doctor about taking anti-nausea medicine


TIREDNESS/FATIGUE

- Track your energy level throughout the day, and have it on-hand to discuss with your doctor
- Balance rest and activity, prioritizing your most necessary activities for when you may have the most energy
- Staying hydrated and eating foods high in protein may increase your energy levels
- If feelings/emotions are disturbing your sleep, talk to your doctor about a referral to a specialist

These are not all the possible side effects of KRAZATI. Call your doctor for medical advice about side effects. You may report side effects to the FDA at 1-800-FDA-1088. You may also report side effects to 1-844-647-2841.

Please read the Full Important Safety Information on pages 9-10 and please see the [Full Prescribing Information, including Patient Information.](#)

Not an actual patient.



At Bristol Myers Squibb, We Provide Support With Purpose

You are the reason behind what we do. The BMS Access Support® program is focused on helping you access your prescribed BMS medicine. If you were prescribed KRAZATI® (adagrasib), you are eligible to enroll in BMS Access Support. The program can help you with:



Coverage Assistance

Upon your request, BMS Access Support may be able to help you review your insurance benefits and understand your coverage for KRAZATI.*

If your insurer requires prior authorization, BMS Access Support may be able to provide you and your doctor information about this requirement.

In the event of a coverage delay or denial, you may be eligible for a bridge program to cover your treatment.† Please call BMS Access Support at 1-800-861-0048 for more information about offerings for your medication.



Financial Support

If you are an eligible commercially-insured patient, you may pay as little as \$0 per one-month supply.† If you are insured through a government program or you do not have insurance, BMS Access Support can provide you with information regarding independent charitable foundations.‡



Free Trial Offer

A Free Trial Offer may be available if you were newly prescribed KRAZATI.†



Educational Resources

Understanding the insurance process and accessing your treatment can be challenging. BMS Access Support offers a library of resources that can help you better understand your healthcare coverage and guide you through steps in your treatment journey.

*The accurate completion and submission of reimbursement- or coverage-related documentation to the patient's insurance plan is the responsibility of the provider and patient. Bristol Myers Squibb and its agents cannot guarantee coverage for any medication or treatment.

†Restrictions apply. Please [click here](#) for full Terms and Conditions, including complete eligibility requirements.

‡It is important to note that charitable foundations are independent from Bristol-Myers Squibb Company and have their own eligibility criteria and evaluation process. Bristol Myers Squibb cannot guarantee that a patient will receive assistance.

We're here for you.

Coverage assistance, educational resources, and financial support options may be available through **BMS Access Support**



Call a Patient Access Specialist at
1-800-861-0048, 8 AM to 8 PM ET, Monday – Friday



Find resources and enrollment information at
www.BMSAccessSupport.com

USE AND IMPORTANT SAFETY INFORMATION

What is KRAZATI?

KRAZATI is a prescription medicine used in adults:

- alone to treat non-small cell lung cancer (NSCLC)
 - that has spread to other parts of the body or cannot be removed by surgery, **and**
 - whose tumor has an abnormal KRAS G12C gene, **and**
 - who have received at least one prior treatment.

Your healthcare provider will perform a test to make sure that KRAZATI is right for you.

It is not known if KRAZATI is safe and effective in children.

IMPORTANT SAFETY INFORMATION

Before taking KRAZATI, tell your healthcare provider about all of your medical conditions, including if you:

- have any heart problems, including heart failure and congenital long QT syndrome
- have liver problems
- are pregnant or plan to become pregnant. It is not known if KRAZATI can harm your unborn baby
- are breastfeeding or plan to breastfeed. It is not known if KRAZATI passes into your breastmilk. Do not breastfeed during treatment and for 1 week after your last dose of KRAZATI

Tell your healthcare provider about all the medicines you take, including prescription and over-the-counter medicines, vitamins, and herbal supplements. KRAZATI can affect the way other medicines work, and other medicines can affect how KRAZATI works.

KRAZATI can cause serious side effects, including:

- **Stomach and intestinal (gastrointestinal) problems.** Stomach and intestinal side effects, including nausea, diarrhea, or vomiting, are common with KRAZATI but can also sometimes be severe. KRAZATI can also cause serious stomach and intestinal side effects such as bleeding, obstruction, inflammation of the colon (colitis), and narrowing (stenosis)
 - **Call your healthcare provider if you develop any of the signs or symptoms of stomach or intestinal problems listed above during treatment with KRAZATI**
 - Your healthcare provider may prescribe an antidiarrheal medicine or anti-nausea medicine, or other treatment, as needed
- **Changes in the electrical activity of your heart called QTc prolongation.** Certain changes can occur in the electrical activity of your heart during treatment with KRAZATI, and can be seen on a test called an electrocardiogram (ECG or EKG). QTc prolongation can increase your risk for irregular heartbeats that can be life-threatening, such as torsades de pointes, and can lead to sudden death
 - You should not take KRAZATI if you have congenital long QT syndrome or if you currently have QTc prolongation. See **"Before taking KRAZATI, tell your healthcare provider about all of your medical conditions, including if you:"**
 - Your healthcare provider should monitor the electrical activity of your heart and the levels of body salts in your blood (electrolytes) especially potassium and magnesium before starting and during treatment with KRAZATI if you have heart failure, a slow heart rate, abnormal levels of electrolytes in your blood, or if you take a medicine that can prolong the QT interval of your heartbeat
 - **Tell your healthcare provider if you feel dizzy, lightheaded, or faint, or if you get abnormal heartbeats during treatment with KRAZATI**
- **Liver problems.** Abnormal liver blood test results are common with KRAZATI and can sometimes be severe. Your

Please read the additional Important Safety Information on the next page and please see the Full Prescribing Information, including Patient Information.

IMPORTANT SAFETY INFORMATION (CONTINUED)

healthcare provider should do blood tests before starting and during treatment with KRAZATI to check your liver function. Tell your healthcare provider right away if you develop any signs or symptoms of liver problems, including:

- your skin or white part of your eyes turns yellow (jaundice), dark or “tea-colored” urine, light-colored stools (bowel movements), tiredness or weakness, nausea or vomiting, bleeding or bruising, loss of appetite, pain, aching, or tenderness on the right side of your stomach area (abdomen)
- **Lung or breathing problems.** KRAZATI may cause inflammation of the lungs that can lead to death. Tell your healthcare provider or get emergency medical help right away if you have new or worsening shortness of breath, cough, or fever

The most common side effects

- The most common side effects of KRAZATI when used alone for NSCLC include: nausea, diarrhea, vomiting, tiredness, muscle and bone pain, kidney problems, swelling, decreased appetite, trouble breathing

Certain abnormal blood test results are common during treatment with KRAZATI. Your healthcare provider will monitor you for abnormal blood tests and treat you if needed.

KRAZATI may cause fertility problems in males and females, which may affect your ability to have children. Talk to your healthcare provider if this is a concern for you.

These are not all of the possible side effects of KRAZATI. Call your doctor for medical advice about side effects. You may report side effects to the FDA. Visit fda.gov/medwatch, or call 1-800-FDA-1088. You may also report side effects to 1-844-647-2841.

Please see the [Full Prescribing Information, including Patient Information.](#)

KRAZATI[®]

(adagrasib) | 200 mg
TABLETS

KRAZATI: Things to Remember



43% saw tumors shrink or disappear

Based on 112 people, of whom 1 person saw all signs of cancer disappear and 47 people saw a decrease in tumor size.

- In a clinical trial, 116 adults with NSCLC were given KRAZATI. The trial evaluated how many patients responded to KRAZATI, meaning their tumors shrank or disappeared, as well as how long the tumor responded to KRAZATI
- Recommended dosage is 600 mg twice daily
- The most common side effects of KRAZATI include nausea, diarrhea, vomiting, tiredness, muscle and bone pain, kidney problems, swelling, breathing trouble, and decreased appetite

KRAZATI is not chemotherapy—it is an oral targeted therapy designed to target KRAS G12C to help fight specific proteins that help cause tumors to grow and spread throughout the body.

Important Considerations: The approval of KRAZATI in these patients is based on a study that measured the size of tumor shrinkage.

SELECT IMPORTANT SAFETY INFORMATION

KRAZATI can cause serious side effects, including:

- **Lung or breathing problems.** KRAZATI may cause inflammation of the lungs that can lead to death. Tell your healthcare provider or get emergency medical help right away if you have new or worsening shortness of breath, cough, or fever

Please read the Full Important Safety Information on pages 9-10 and please see the Full Prescribing Information, including Patient Information.

References: **1.** KRAZATI. Prescribing information. Mirati Therapeutics, Inc.; 2022. **2.** Cox AD, Fesik SW, Kimmelman AC, Luo J, Der CJ. Drugging the undruggable RAS: Mission possible? *Nat Rev Drug Discov.* 2014;13(11):828-851. **3.** Fernández-Medarde A, Santos E. Ras in cancer and development diseases. *Genes Cancer.* 2011;2(3):344-358. **4.** Jänne PA, Riely GJ, Gadgeel SM, et al. Adagrasib in non-small-cell lung cancer harboring a KRAS^{G12C} mutation. *N Engl J Med.* 2022;387(2):120-131. **5.** Eisenhauer EA, Therasse P, Bogaerts J, et al. New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1). *Eur J Cancer.* 2009;45(2):228-247. **6.** Diarrhea: cancer treatment side effect. National Cancer Institute. Updated September 24, 2021. Accessed October 27, 2022. <https://www.cancer.gov/about-cancer/treatment/side-effects/diarrhea> **7.** Nausea and vomiting and cancer treatment - side effects. National Cancer Institute. Accessed October 27, 2022. <https://www.cancer.gov/about-cancer/treatment/side-effects/nausea-vomiting> **8.** Fatigue and cancer treatment. National Cancer Institute. Updated September 23, 2021. Accessed October 27, 2022. <https://www.cancer.gov/about-cancer/treatment/side-effects/fatigue>